Xenon Pharmaceuticals pauses enrollment for azetukalner trials
Xenon Pharmaceuticals said it is voluntarily pausing trial enrollment for azetukalner for depression and bipolar treatment after adverse events, pending consultation.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.